|4Jul 23, 7:32 PM ET

Medmira Capital Ltd. 4

4 · HCW Biologics Inc. · Filed Jul 23, 2021

Insider Transaction Report

Form 4
Period: 2021-07-22
Transactions
  • Conversion

    Common Stock

    2021-07-22+730,5193,587,661 total
  • Conversion

    Series B Redeemable Preferred Stock

    2021-07-222,857,1420 total
    Common Stock (2,857,142 underlying)
  • Conversion

    Common Stock

    2021-07-22+2,857,1422,857,142 total
  • Conversion

    Series C Redeemable Preferred Stock

    2021-07-22730,5190 total
    Common Stock (730,519 underlying)
Footnotes (2)
  • [F1]Each share of the Series B Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.
  • [F2]Each share of the Series C Redeemable Convertible Preferred Stock automatically converted into one share of the Issuer's Common Stock, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION